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Valproic acid (2-propylpentanoic acid) is an anticonvulsant drug, widely used in the
treatment of epilepsy, affecting both children and adults (1, 2). It is also used to treat bi-
polar disorder and to prevent migraine headaches (3).
Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) is used in clini-
cal practice to aid the treatment of patients with epilepsy. In order to obtain information
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A bioanalytical HPLC method with UV detection for the
determination of the antiepileptic drug valproic acid in
human saliva has been developed and validated. Saliva
represents an alternative matrix for therapeutic monitor-
ing of antiepileptic drugs due to the increasing interest
in free drug concentration. The proposed method invol-
ved solid-phase extraction for sample preparation and
yielded very good mean recoveries of 99.4 % and 97.9 %
for valproic acid and IS, respectively. The calibration
function for valproic acid was linear over the concentra-
tion range of 1.0–50.0 mg mL–1 (R2 = 0.9989). Within-run
and between-run precision and accuracy were studied
at four concentrations and RSDs were less than 7.3 and
2.2 %, while accuracy values were higher than 96.8 and
97.5 %, respectively. The described method provides sen-
sitivity, linearity, precision, accuracy and is suitable for
analyses of valproic acid in saliva samples.
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for TDM, the development of a reliable analytical method for the determination of AEDs
in biological fluids is of great importance (4). Serum and plasma represent the matrices
of choice for TDM of AEDs. Their concentration can be also measured in saliva, urine,
cerebrospinal fluid and tears (5). In the last 30 years, saliva has been advocated as an al-
ternative matrix and the increasing interest in free drug concentration monitoring has
provided a renewed impetus in saliva monitoring of antiepileptic drugs (6). The mea-
surement of free drug concentration is desirable but it is difficult to achieve in practice
because the processes as equilibrium of dialysis and ultracentrifugation are time-consu-
ming, expensive and require large sample volumes (7). For a highly protein-bound drug,
such as VPA ( 90 %, which results in a free fraction of only 10 %), saliva is the most suit-
able matrix for measuring the free concentration, because saliva can be expected to be-
have as a natural ultra filtrate of plasma. It is also an attractive alternative, because sa-
liva collection is noninvasive, painless, simpler, less stressful, does not involve fear and
discomfort, and complications of infection and thrombosis. Saliva sampling is especially
useful in paediatric, geriatric and patients with disabilities (8).
Several methods involving immunoassay (9), gas-chromatography (10), high-per-
formance liquid chromatography (11, 12) and LC-MS/MS (13) have been reported for
the determination of valproic acid in biological fluids. According to our knowledge, no
HPLC-UV methods for the determination of valproic acid in saliva have been published
so far.
The aim of our study was to develop and validate a reliable HPLC-UV detection
method for the determination of VPA in saliva using the solid phase extraction proce-
dure for the sample preparation.
EXPERIMENTAL
Chemicals and reagents
Valproic acid sodium salt and octanoic acid (internal standard, IS), analytical stan-
dards were purchased from Sigma-Aldrich Inc., USA. Methanol (HPLC grade) and ace-
tonitrile (HPLC grade) were purchased from Merck, Germany. Potassium dihydrogen phos-
phate and phosphoric acid for buffer preparation were of analytical grade and were also
obtained from Merck. For all analyses, HPLC grade water purified with a TKA_LAB
Reinstwasser system (Niederelbert, Germany) was used. SampliQ OPT cartridges used
for sample preparation were procured from Agilent Technologies, USA.
Collection of saliva samples
Saliva was collected from healthy volunteers (for method validation) and from epi-
leptic patients. Saliva samples were collected at least 2 hours after the intake of the last
dose of valproic acid. Patients were instructed to first rinse the mouth thoroughly and
repeatedly with water to remove any remnants of food or medication. About five milli-
litre of nonstimulated liquid clear saliva was collected into collecting tube. Saliva sam-
ples were than frozen and stored at –20 °C until analysis.
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Participation of each subject was voluntary and could be cancelled by any individ-
ual at any time during the study (according to the Helsinki II declaration). The Ethics
Committee at the Faculty of Pharmacy and the Faculty of Medicine, Ss. Cyril and Me-
thodius University – Skopje, approved the research protocol for this study and all volun-
teers signed the Study Informed Consent form.
Chromatographic conditions
The assay was performed on an Agilent 1200 series HPLC system (Agilent Technol-
ogies) equipped with a vacuum degasser (G1322A Degasser), quaternary pump (G1311A
QuatPump), autosampler (G1329A ALS), column compartment (G1316A TCC), diode ar-
ray detector (G1315D DAD), and ChemStation for LC 3D software for data handling.
Separation was performed on a Zorbax Eclipse XDB C-18 (150 ´ 4.6 mm; 5 mm) col-
umn with a mobile phase of acetonitrile-phosphate buffer (pH 3.0; 0.02 mol L–1) (40 : 60,
V/V). The analyses were run at a flow rate of 1 mL min–1, volume of injection 100 mL and
temperature 25 °C. Detection was made at 210 nm.
Preparation of standards and quality control samples
Stock standard solutions of valproic acid (500 mg mL–1) and internal standard of oc-
tanoic acid (364 mg mL–1) were prepared by dissolution in methanol. Working solutions
were obtained by serial dilutions of the stock solution of valproic acid with purified wa-
ter. Stock solutions were stored at 2–8 °C and were stable for one month.
Seven calibration standards of valproic acid were made by spiking the blank saliva
aliquots with an appropriate volume of the working solutions of valproic acid, giving
the final concentration of 1.0 to 50.0 mg mL–1, containing the IS at a constant concentra-
tion of 36.4 mg mL–1. Calibration curve was constructed using the ratio of peak areas of
valproic acid and octanoic acid as a function of valproic acid concentration.
Four levels of quality control (QC) samples were prepared at concentrations of 1.0
mg mL–1 (lower limit of quantitation), 5.0 mg mL–1 (low QC sample), 10.0 mg mL–1 (me-
dium QC sample) and 20.0 mg mL–1 (high QC sample), in the same way as described
above for the calibration standards, and stored at –20 °C until analysis. The QC samples
were used to assess the accuracy and precision of the method.
Each spiked saliva sample was processed as described in sample preparation.
Sample preparation
Preparation of samples was based on the solid-phase extraction (SPE) as a selective
method for sample preparation. Frozen saliva samples collected from healthy volunteers
and epileptic patients were allowed to thaw at room temperature before being centri-
fuged at 3000 rpm for 15 min. This procedure is done in order to overcome the difficul-
ties resulting from the high viscosity of freshly obtained saliva (highly mucous, stringy
and sticky consistence). The supernatant from an epileptic patient’s saliva was transfer-
red into the Eppendorf tube and spiked with 100 mL IS (36.4 mg mL–1) and 20 mL of 10 %
H3PO4, while the supernatant from blank saliva was previously spiked with valproic acid
and IS as described in the section Preparation of standards and quality control samples. The
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mixture was vortex-mixed for 30 s and loaded into SampliQ OPT cartridges (30 mg/1 mL)
previously conditioned according to the following steps: a) conditioning with 1 mL me-
thanol; b) equilibration with 1 mL water; c) loading of 1 mL saliva sample; d) washing
twice with 1 mL water and 1 mL 10 % methanol; e) elution with 200 mL 90 % methanol.
The eluate was transferred to microvials and the autosampler was programmed to inject
100 mL into the HPLC system.
Bioanalytical method validation
Method validation was conducted according to the Guideline on Validation of Bio-
analytical Methods of the European Medicines Agency (14).
Selectivity. – Selectivity was assessed by comparing the chromatograms of blank sa-
liva samples from six sources and those obtained from a saliva sample spiked with ana-
lyte(s) of interest and internal standard.
Linearity and range. – Prior to validation of the bioanalytical method, the concentra-
tion range should be justified based on scientific information. The range should be cov-
ered by the calibration line range, defined by the lower limit of quantitation (LLOQ) and
the upper limit of quantitation (ULOQ).
A minimum of six calibration concentration levels should be used, excluding the
blank sample (processed matrix sample without analyte and without IS) and a zero sam-
ple (processed matrix with IS). The acceptable criterion for each standard concentration
was ± 15 % of the nominal value, except for the LLOQ which was ± 20 %.
Accuracy and precision. – Accuracy and precision were assessed on samples spiked
with known amounts of the analyte, the quality control samples (QC samples). Accuracy
and precision were evaluated for the values of the QC samples obtained within a single
run (the within-run) and in different runs (the between-run). Within-run accuracy and
precision were determined at least five samples per concentration level on LLOQ, low,
medium and high QC samples in a single run. Between-run accuracy and precision were
assessed by five determinations per concentration per run on LLOQ, low, medium and
high QC samples from three runs analysed on at least two different days.
Recovery. – Recovery describes the extraction efficiency of the analytical process. Re-
covery was calculated by comparing the peak areas of analytes obtained from the SPE
processed blank saliva sample previously spiked with analytes vs. peak areas obtained
from an SPE processed blank saliva sample, and then spiked with analytes, representing
100 % recovery (15).
Stability
Stability test was performed on three replicates of low and high QC samples after
24 h at room temperature (short-term stability), after three freeze-thaw cycles, autosam-
pler stability for 10 h and on samples stored for 30 days at –20 °C (long-term stability).
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RESULTS AND DISCUSSION
Optimisation of the SPE procedure and development of the RP HPLC-UV method
During the optimization of the chromatographic conditions, different mobile phases
(different pH values of the buffer, and also different organic to aqueous phase ratios)
were evaluated. The best results of good separation of valproic acid and IS were obtai-
ned with the mixture of acetonitrile-phosphate buffer pH 3.0 (40:60, V/V) with the re-
tention times of valproic acid and octanoic acid of 9.8 and 12.4 min, respectively.
During the solid phase extraction procedure, two different types of SPE columns (Sam-
pliQ OPT and SampliQ C18 cartridges) and different steps of washing and elution were
evaluated. At first, elution with 1 mL acetonitrile was tested; valproic acid was comple-
tely retained by the cartridge. Similar results, with low recovery, were obtained using
pure methanol or an acetonitrile-methanol (50:50, V/V) mixture. The best results for re-
covery of 99.4 % and 97.9 % for valproic acid and IS, respectively, were obtained using
Agilent SampliQ OPT cartridges and the SPE procedure is described in the sample prepa-
ration section.
Validation
Selectivity. – The chromathograms for blank saliva, blank saliva spiked with valpro-
ic acid and octanoic acid are presented in Fig. 1. No interfering peaks were observed at
the retention times of analyte or IS.
Linearity. – The calibration line was constructed with seven calibration standards
within the range of 1.0–50.0 mg mL–1, including LLOQ. Coefficient of determination R2
was 0.9989 and the LLOQ was 1 mg mL–1.
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assay (n = 5)
1.00 1.04 ± 0.08 104.3 7.3
5.00 4.84 ± 0.13 96.8 2.7
10.00 9.96 ± 0.08 99.7 0.8
20.00 19.84 ± 0.26 99.2 1.3
Between-run
assays (n = 30)
1.00 0.99 ± 0.02 99.4 2.2
5.00 4.88 ± 0.04 97.5 0.7
10.00 10.04 ± 0.10 100.4 1.0
20.00 19.85 ± 0.22 99.2 1.1
a Mean ± SD.
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Fig. 1. RP-HPLC chromatograms obtained from: a) blank saliva (drug free saliva), b) blank saliva
spiked with valproic acid (50 mg mL–1) and octanoic acid (36.2 mg mL–1), c) blank saliva spiked with
valproic acid at LLOQ level (1.0 mg mL–1) and octanoic acid (36.2 mg mL–1), d) blank saliva spiked
with valproic acid at high QC level (20 mg mL–1) and octanoic acid (36.2 mg mL–1), after the SPE pro-
cedure. Unnamed peaks are the endogenous components of saliva.
Accuracy and precision. – The within-run and between-run accuracy and precision are
shown in Table I. Within-run assay precision ranged from 0.8 to 7.3 %, while within-run
assay accuracy ranged from 96.8 to 104.3 %. The between-run precision and accuracy
ranged from 0.7 to 2.2 % and 97.5 to 100.4 %, respectively. The chromatograms of quality
control samples at two concentration levels of valproic acid (LLOQ and high QC sam-
ples) are shown in Figure 1.
Recovery. – The recoveries of valproic acid at four concentration levels (1.0, 5.0, 10.0
and 20.0 mg mL–1) were in the range 96.8–99.4 %, and the recovery of IS was 97.9 %.
These results indicate good recoveries for valproic acid and IS, which means that the
proposed SPE procedure could be applied to the determination of saliva valproic acid in
epileptic patients.
Stability
Stability experiments were performed by evaluating the stability of valproic acid and
octanoic acid stock solutions and saliva samples under different conditions. Stock solu-
tions of valproic acid and IS were stable at room temperature for 24 h (accuracy: 99.3
and 99.7 %, respectively) and at 2–8 °C for 30 days (accuracy: 100.5 and 99.8 %, respec-
tively). It was shown that the human saliva samples spiked with valproic acid were sta-
ble after three freeze-thaw cycles, after 12 h in autosampler and at room temperature for
24 h. The study indicated that the saliva samples could be stored at –20 °C for 30 days.
The respective VPA concentrations ranged from 92.2 to 104.9 %. The results are presen-
ted in Table II.
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Table II. Stability of valproic acid in saliva under various conditionsa
Initaial concentration
















(30 days at –20 °C)
1.02 1.07 3.9
19.98 20.10 1.1
a n = 3.
The obtained results indicate that the analyte is stable under any of the storage con-
ditions described above and that no stability related problems would be expected dur-
ing the routine saliva sample analysis.
Analysis of patient saliva
The validated method was applied to saliva samples collected from epileptic pa-
tients (currently 10 patients are enrolled in the study, age range 18–55 years) under oral
chronic VPA therapy. The chromatograms of saliva samples from two patients, one who
received 500 mg day–1 and the other who received 800 mg day–1 VPA, collected 2 h after
the last drug intake, are presented in Fig. 2, and the VPA concentrations of 2.17 and 6.74
mg mL–1, respectively, were found by interpolation on the calibration curve. Results of
the assays of saliva samples of 10 patients (5 patients who received 500 mg day–1 VPA
and 5 patients who received 800 mg day–1 VPA) were 1.85 ± 0.23 and 7.24 ± 0.53 mg mL–1,
resp.
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Fig. 2. RP-HPLC chromatograms of saliva samples obtained from a patient treated with a) 500 mg
day–1 and b) 800 mg day–1 of valproic acid, collected 2 h after the last drug intake. Unnamed peaks
are the endogenous components of saliva.
The method gives promising results with saliva samples and was shown to be use-
ful for easy therapeutic drug monitoring of valproic acid in epileptic patients after val-
proic acid oral administration. Additional collection of data is needed in order to con-
firm this trend.
Having in mind that epileptic patients are often treated with polytherapy, to evalu-
ate the selectivity of the proposed method, saliva samples taken from patients simulta-
neously treated with carbamazepine, lamotrigine and topiramate (commonly prescribed
drugs along with VPA in Macedonia) were analysed. No chromatographic interference
was observed in the retention times of VPA and IS, hence the method could be used even
when other antiepileptic drugs were co-administered.
CONCLUSIONS
A simple, sensitive and reliable RP HPLC-UV method has been developed for deter-
mination of valproic acid in human saliva after solid-phase extraction. The method al-
lows determination of valproic acid at low concentration without prior derivatization.
Validation data demonstrate that the proposed bioanalytical method is selective, sensi-
tive, precise and accurate and therefore suitable for determination of saliva concentra-
tions of this antiepileptic drug. Saliva levels reflect the free and therefore the pharmaco-
logically active fraction of valproic acid and may be determined after collecting samples
in a convenient and noninvasive way. Further investigations are needed in order to de-
termine the correlation between saliva and plasma concentrations of valproic acid and
to assess the feasibility of salivary valproic acid determination for routine therapeutic
drug monitoring.
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S A @ E T A K
Razvoj i validacija bioanaliti~ke LC-UV metode s ekstrakcijom
na ~vrstoj fazi za odre|ivanje valproi~ne kiseline u slini
JASMINA TONIC-RIBARSKA, ARLINDA HAXHIU, ZORAN STERJEV, GORDANA KITEVA,
LjUBICA SUTURKOVA i SUZANA TRAJKOVIC-JOLEVSKA
U radu je opisana i validirana bioanaliti~ka HPLC metoda s UV detekcijom za odre-
|ivanje antiepileptika valproi~ne kiseline u slini ~ovjeka. Zbog sve ve}eg interesa za pra-
}enje koncentracije slobodnog lijeka slina predstavlja alternativni matriks za pra}enje anti-
epileptika. Predlo`ena metoda u pripremi uzorka uklju~uje ekstrakciju na ~vrstoj fazi.
Dobiven je vrlo dobar srednji analiti~ki povrat od 99,4 % i 97,9 % za valproi~nu kiselinu,
odnosno IS. Kalibracijska funkcija za valproi~nu kiselinu bila je linearna u koncentracij-
skom podru~ju od 1,0–50,0 mg mL–1 (R2 = 0,9989). Preciznost i to~nost procijenjene unu-
tar jednog i vi{e mjernih dana dale su RSD ni`e od 7,3 i 2,2 %, te vrijednosti za to~nost
iznad 96,8, odnosno 97,5 %. Opisana metoda je dovoljno osjetljiva, precizna i to~na, osi-
gurava linearni odgovor te je pogodna za analizu valproi~ne kiseline u slini.
Klju~ne rije~i: valproi~na kiselina, slina, ekstrakcija na ~vrstoj fazi, visokotla~na teku}inska kromato-
grafija s visokom u~inkovitosti, validacija
Institute of Applied Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, University »Ss Cyril
and Methodius«, Skopje, Macedonia
Department of Pharmacy, Medical Sciences Faculty, State University of Tetova, Tetovo, Macedonia
220
J. Tonic-Ribarska et al.: Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination
of valproic acid in saliva, Acta Pharm. 62 (2012) 211–220.
